Evidence map›Paper›PMID 29470654›Full record

ReviewDer Urologe. Ausg. A2018

[Molecular characterization of penile cancer : Literature review of new prognostic markers and potential therapeutic targets].

M May, S D Brookman-May, T H Ecke, M Burger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

M MayUrologische Klinik, Klinikum St. Elisabeth Straubing, St. Elisabeth-Str. 23, 94315, Straubing, Deutschland. matthias.may@klinikum-straubing.de.
S D Brookman-MayUrologische Klinik, Ludwigs-Maximilians-Universität (LMU) München, München, Deutschland.
T H EckeUrologische Klinik, Helios-Klinikum Bad Saarow, Bad Saarow, Deutschland.
M BurgerUrologische Klinik, Caritas-Krankenhaus St. Josef, Universität Regensburg, Regensburg, Deutschland.
Barmherzige Brüder Klinikum St. Elisabeth in Straubing · DECaritas-Krankenhaus St. Josef · DEHelios Hospital Bad Saarow · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinoma of the penis (SCCP) is a rare cancer type in Western industrialized nations; nevertheless, it shows an aggressive course of disease in advanced tumor stages with accordantly high recurrence and progression rates. While molecular biomarkers are not established in clinical routine for the management of SCCP patients yet, the accordant unmet need is enormous, as adequate biomarkers would be meaningful for prognostic determination, planning of modality and extent of primary therapy, indication for inguinal lymph node resection, adjuvant treatment, and as potential targets for specific systemic treatment. SCCP regularly develops from a precursor lesion. In this regard, human papillomavirus (HPV)-dependent and -independent pathways are differentiated. The potential for specific target therapy options is mainly based on the decoding of genetic and epigenetic signatures of distinct molecular pathways. In order to develop targeted and personalized treatment strategies based on molecular pathways, an increase in translational research in large multi-institutional collaborations must be promoted. This review article aims to summarize the current status of research concerning molecular changes related to SCCP under separate consideration of prognostic molecular markers, on the one hand, and biomarkers considered potential therapeutic targets, on the other hand. In addition, previous research activities of our own working group on this topic are briefly described.

Indexed as

Biomarkers, TumorCarcinogenesisCarcinoma, Squamous CellCorrelation of DataCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDNA Mutational AnalysisGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKi-67 AntigenLymphatic MetastasisLymph NodesMaleNeoplasm GradingNeoplasm StagingBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16Ki-67 AntigenTumor Suppressor Protein p53BiomarkersCarcinogenesisLymph nodesSquamous cell carcinomaTumor suppressor genes

Identifiers

PMID29470654
OpenAlexW2793312293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.